Clinical trials: Drusen
Age-Related Macular Degeneration
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
- Trial name
- COMPLETE (NCT00935883)
- Testing
- Eculizumab, Saline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Philip J. Rosenfeld, MD, PhD
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Retinal Drusen
Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration
This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen.
- Trial name
- NCT02569892
- Testing
- Pascal Retinal Laser Photocoagulator
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Stanford University
Glaucoma, Glaucoma Suspect
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
The goal is to conduct a 5-year prospective, randomized controlled trial to test an innovative, community-based intervention using posterior and anterior fundus photography of the optic nerve and macula and intraocular eye…
- Conditions
- Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension
- Trial name
- NCT02390245
- Testing
- Free Eye Screenings, Enhanced Intervention, Usual Care
- Where
- United States
- Volunteers
- 906 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.